Feedback on student analysis on the artickle :Issue:This article addresses a concern raised by US-based direct-to-consumer genetic testing (DTC-GTs) companies. The current self-regulatory operation, including the collection, use, and sharing of genetic data, raises concerns associated with moral and legal obligations. It focuses on whether third-party disclosure complies with sufficient informed consent. It examines whether DTC-GTs companies have fair and transparent rules and practices for treating both present and future customers. Rule:The federal and state laws regarding genetic testing and the data form appropriate rules. The federal authorities, such as the FDA, the FTC, and the Centers for Medicare and Medicaid Services (CMS), through the Clinical Laboratory Improvements Act (CLIA), govern the DTC-GT industry. This is because notable regulatory frameworks like the Health Insurance Portability and Accountability Act of 1996 (HIPPA) and the federal Genetic Information Nondiscrimination Act of 2008 (GINA) do not directly apply to the DTC-GT sector. The CMS and CLIA guarantee the legitimacy of genetic testing and the data it produces. The FDA controls genetic testing linked to health in order to prevent deceptive advertising and medical discretion